Company intelligence / Profile preview

THEODON

Nyack, New York, United States

Ownership: Private
Development stage: Other

Overview

THEODON is a private healthcare-focused commercial strategy consultancy rather than a drug developer. The firm appears to advise biotechnology, life sciences, health tech, and med-tech organizations on commercialization strategy, business transformation, and capability building. Publicly available information indicates it was founded in 2018 by Karim Mikhail after his tenure at Merck, and has been described as a global commercial strategy consultancy serving biotech and life science clients. Available sources do not indicate that THEODON has an in-house therapeutic pipeline, proprietary drug platform, or clinical-stage assets.

Industry: Consulting

Beyond the preview

Go deeper on THEODON.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THEODON.

Explore the full profile